Evidence map›Paper›PMID 30455245›Full record

ArticleAntimicrobial agents and chemotherapy2019

Preexposure to Isavuconazole Increases the Virulence of

Sebastian Wurster, Russell E Lewis, Nathaniel D Albert, Dimitrios P Kontoyiannis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. The Impact of Dimitrios P. Kontoyiannis on Mucormycosis Research.Journal of fungi (Basel, Switzerland) · 2024
    Article
  3. AlternativeFrontiers in cellular and infection microbiology · 2024
    Review
  4. The utility ofFrontiers in immunology · 2024
    Review
  5. What Is New in Pulmonary Mucormycosis?Journal of fungi (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Fungal Priming: Prepare or Perish.Journal of fungi (Basel, Switzerland) · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Animal Models to Study Mucormycosis.Journal of fungi (Basel, Switzerland) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sebastian WursterDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7784-7256
Russell E LewisClinic of Infectious Diseases, S'Orsola-Malpighi Hospital, and Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Nathaniel D AlbertDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Dimitrios P KontoyiannisDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA dkontoyi@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breakthrough mucormycosis in patients receiving isavuconazole prophylaxis or therapy has been reported. We compared the impact of isavuconazole and voriconazole exposure on the virulence of clinical isolates of

Indexed as

AnimalsAntifungal AgentsAspergillus fumigatusDrosophila melanogasterFemaleMucoralesNitrilesPyridinesRhizopusTriazolesVirulenceAntifungal AgentsisavuconazoleNitrilesPyridinesTriazolesAspergillus fumigatusDrosophila melanogasterisavuconazoleRhizopus arrhizus

Identifiers

PMID30455245
PMCPMC6355575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.